Skip to main content
Premium Trial:

Request an Annual Quote

Decipher Biosciences, Dendreon Pharmaceuticals Ink Prostate Cancer Research Deal

NEW YORK (GenomeWeb) — Decipher Biosciences — formerly GenomeDx Biosciences — announced today that it has signed an agreement to help Dendreon Pharmaceuticals identify patients who are likely to respond to its prostate cancer therapy Provenge (sipuleucel-T).

Provenge is a US Food and Drug Administration-approved autologous cellular immunotherapy. Under the terms of the deal, the Decipher assay will be used to assess the biological behavior of tumors from patients enrolled in a phase III study of Provenge. It will also evaluate tumor gene expression signatures that may be associated with Provenge response..

The Decipher assay is designed to provide a genomic assessment of tumor aggressiveness for individual patients and is derived from the San Diego-based company's Genomics Resource Information Database of urologic tumor genomic profiles.

Additional terms were not disclosed

The Scan

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.

Sequencing Analysis Examines Gene Regulatory Networks of Honeybee Soldier, Forager Brains

Researchers in Nature Ecology & Evolution find gene regulatory network differences between soldiers and foragers, suggesting bees can take on either role.

Analysis of Ashkenazi Jewish Cohort Uncovers New Genetic Loci Linked to Alzheimer's Disease

The study in Alzheimer's & Dementia highlighted known genes, but also novel ones with biological ties to Alzheimer's disease.

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.